<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01849510</url>
  </required_header>
  <id_info>
    <org_study_id>SPIME2013</org_study_id>
    <nct_id>NCT01849510</nct_id>
  </id_info>
  <brief_title>Efficacy of Dose Intensified Radiotherapy of Spinal Metastases by Hypofractionated Radiation and IGRT hfSRT Mediated Boost</brief_title>
  <acronym>SPIN-MET</acronym>
  <official_title>Efficacy of Dose Intensified Radiotherapy of Spinal Metastases of Solid Tumors by Dose Increased, Homogeneous Radiation of Vertebral Body and Simultaneous Application of Stereotactic Boost.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Erlangen-Nürnberg Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Erlangen-Nürnberg Medical School</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Spinal metastases indicate for an incurable course of disease. Local tumor control after
      palliative radiotherapy of spinal metastases (10x3 Gy, 1x8Gy) is between 61 to 81%. In 30% of
      patients, therapy fails locally within two years associated with further symptoms that are
      difficult to treat, because a further radiation of already radiated vertebra leads to a
      higher rate of myelitis. This trial aims to improve local tumor control and control of pain
      by radiotherapy with increase in total and single dose. Dose elevation is realized by
      simultaneous, integrated boost mediated by image-guided stereotactic radiotherapy (IGRT &amp;
      hfSRT) and by elevation of elective dose in vertebral body with 12x3 Gy (standard: 10x3 Gy).
      Primary endpoint is local tumor control (time up to progression). Secondary endpoints are
      pain control associated with quality of live, severity of acute and chronic adverse effects
      and overall survival. It is planned to recruit a total number of 155 patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>tumor control (time up to progression)</measure>
    <time_frame>up to progression (MR-imaging), max. 5 years after therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>severity of acute and chronic adverse effects</measure>
    <time_frame>acute: assessment up to 6 weeks after therapy; chronic: assessment up to 60 months after therapy or up to progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>assessment 60 months after therapy or up to death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain control</measure>
    <time_frame>assessment 60 months after therapy</time_frame>
    <description>by visual analog scala and questionnaires according pain</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">155</enrollment>
  <condition>Spinal Metastases</condition>
  <arm_group>
    <arm_group_label>dose intensified</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>hypofractionated 12x3 Gy + integrated boost 12x4 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>hypofractionated 10x3 Gy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>hypofractionated 12x3 Gy + integrated boost 12x4 Gy</intervention_name>
    <description>hypofractionated, homogeneous radiation (12x3 Gy) with simultaneously administrated, integrated boost (12x4 Gy) mediated by IGRT &amp; hfSRT</description>
    <arm_group_label>dose intensified</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>hypofractionated 10x3 Gy</intervention_name>
    <description>hypofractionated, homogeneous radiation (10x3 Gy)</description>
    <arm_group_label>standard</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  minimum age 18

          -  expectance of life at least 6 months

          -  Karnofsky-Score &gt; 50

          -  1-3 vertebral body metastases

          -  Up to 5 other, macroscopic metastases

          -  effective contraception

          -  geographic reachability of patients

          -  Signed study-specific consent form prior to therapy

          -  no on-treatment participation on other trials

        Exclusion Criteria:

          -  initial required neurosurgical decompression

          -  rapid, neurological deterioration

          -  prior radiotherapy of region for planned radiation

          -  conditions that preclude the application of magnetic resonance tomography

          -  malignancy: multiple myeloma or lymphoma

          -  technical conditions preclude stereotactic irradiation (technical limitations of
             device)

          -  pregnant or nursing women

          -  Fertile patients who refuse effective contraception during study treatment

          -  persistent drug and/or alcohol abuse

          -  patients that are not able or willing to behave according to study protocol

          -  absent attendance for personal, disease related data storage and transfer

          -  on-treatment participation on other trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sabine Semrau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Strahlenklinik, Universitätsklinikum Erlangen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sabine Semrau, MD</last_name>
    <phone>++49(0)9131 85</phone>
    <phone_ext>33968</phone_ext>
    <email>sabine.semrau@uk-erlangen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rainer Fietkau, MD</last_name>
    <phone>++49(0)9131 85</phone>
    <phone_ext>33968</phone_ext>
    <email>st-studiensekretariat@uk-erlangen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabine Semrau, MD</last_name>
      <phone>++49(0) 9131 85</phone>
      <phone_ext>33968</phone_ext>
      <email>sabine.semrau@uk-erlangen.de</email>
    </contact>
    <contact_backup>
      <last_name>Rainer Fietkau, MD</last_name>
      <phone>++49(0) 9131 85</phone>
      <phone_ext>33968</phone_ext>
      <email>st-studiensekretariat@uk-erlangen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Sabine Semrau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rainer Fietkau, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt; Strahlentherapie</name>
      <address>
        <city>Frankfurt/M.</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg, Strahlentherapie</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 18, 2013</study_first_submitted>
  <study_first_submitted_qc>May 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2013</study_first_posted>
  <last_update_submitted>August 9, 2017</last_update_submitted>
  <last_update_submitted_qc>August 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>spinal metastases</keyword>
  <keyword>vertebral body</keyword>
  <keyword>stereotaxis</keyword>
  <keyword>image-guided radiotherapy</keyword>
  <keyword>hypofractionated</keyword>
  <keyword>dose intensified</keyword>
  <keyword>dose elevation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

